Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2003. The report details a specific corporate action regarding share re-purchases executed in accordance with shareholder authority granted at the Annual General Meeting on May 20, 2002.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share re-purchase transaction:
- Shares Purchased: 860,000 ordinary shares
- Purchase Date: February 21, 2003
- Price per Share: 1150.12p
- Transaction Purpose: Cancellation of shares
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. The primary change reported is the reduction of the company's share capital through the cancellation of 860,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is a procedural announcement strictly limited to the execution of the share buyback program.
Key Facts for Investor Verification
- Verify the total number of shares authorized for re-purchase under the May 20, 2002 shareholder resolution to assess remaining capacity.
- Confirm the total cost of the transaction (860,000 shares at 1150.12p) against the company's cash reserves in the most recent full financial report.
- Check subsequent filings to determine if this was an isolated transaction or part of a larger ongoing buyback program.